Reply Letter to "Immunogenicity and Safety of a Quadrivalent High-dose Inactivated Influenza Vaccine Compared with a Standard-dose Quadrivalent Influenza Vaccine in Healthy People Aged 60 Years or Older: a Randomized Phase III Trial"

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2022 Jun 8

PMID 35674507

Authors

Sanjay Hadigal

Laura Colombo

Scott Haughie

Affiliations

Soon will be listed here.

Abstract

A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV) is an important tool to measure the benefit of a given vaccine. Further, NNV evaluates the benefits of a vaccine in preventing and controlling communicable diseases. Considering the target of vaccination and coverage of 75% not met in the elderly in Europe, it is important not to prioritize one vaccine over the other, but rather to increase the vaccine coverage with all the available vaccines.

Citing Articles

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study.

Adams K, Riddles J, Rowley E, Grannis S, Gaglani M, Fireman B Lancet Reg Health Am. 2023; 23:100530.

PMID: 37333688 PMC: 10266334. DOI: 10.1016/j.lana.2023.100530.

Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years.

Kevin Yin J, Pepin S, van Aalst R, Loiacono M, Samson S Hum Vaccin Immunother. 2022; 18(6):2106749.

PMID: 35914122 PMC: 9750711. DOI: 10.1080/21645515.2022.2106749.

References

DiazGranados C, Dunning A, Kimmel M, Kirby D, Treanor J, Collins A . Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014; 371(7):635-45. DOI: 10.1056/NEJMoa1315727. View

Su W, Wang H, Sun C, Li N, Guo X, Song Q . The Association Between Previous Influenza Vaccination and COVID-19 Infection Risk and Severity: A Systematic Review and Meta-analysis. Am J Prev Med. 2022; 63(1):121-130. PMC: 8920881. DOI: 10.1016/j.amepre.2022.02.008. View

Ranganathan P, Pramesh C, Aggarwal R . Common pitfalls in statistical analysis: Absolute risk reduction, relative risk reduction, and number needed to treat. Perspect Clin Res. 2016; 7(1):51-3. PMC: 4763519. DOI: 10.4103/2229-3485.173773. View

Ashraf M, Rajaram S, English P . How the COVID 19 pandemic will shape influenza public health initiatives: The UK experience. Hum Vaccin Immunother. 2022; 18(5):2056399. PMC: 9255027. DOI: 10.1080/21645515.2022.2056399. View

Cohen S, Chui K, Naumova E . Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002-2006. J Am Geriatr Soc. 2011; 59(2):327-32. PMC: 3111961. DOI: 10.1111/j.1532-5415.2010.03271.x. View

Montesinos I, Arrieta-Aldea I, Dicastillo A, Zuccarino F, Sorli L, Guerri-Fernandez R . Comparison of Hospitalized Coronavirus Disease 2019 and Influenza Patients Requiring Supplemental Oxygen in a Cohort Study: Clinical Impact and Resource Consumption. Clin Infect Dis. 2022; 75(12):2225-2238. PMC: 9047197. DOI: 10.1093/cid/ciac314. View

Hashim A, Dang V, Bolotin S, Crowcroft N . How and why researchers use the number needed to vaccinate to inform decision making--a systematic review. Vaccine. 2014; 33(6):753-8. DOI: 10.1016/j.vaccine.2014.12.033. View

Pepin S, Nicolas J, Szymanski H, Leroux-Roels I, Schaum T, Bonten M . Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial. Hum Vaccin Immunother. 2021; 17(12):5475-5486. PMC: 8903946. DOI: 10.1080/21645515.2021.1983387. View

Swets M, Russell C, Harrison E, Docherty A, Lone N, Girvan M . SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022; 399(10334):1463-1464. PMC: 8956294. DOI: 10.1016/S0140-6736(22)00383-X. View

10.

Sandmann F, van Leeuwen E, Bernard-Stoecklin S, Casado I, Castilla J, Domegan L . Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis. Vaccine. 2022; 40(9):1306-1315. PMC: 8861572. DOI: 10.1016/j.vaccine.2022.01.015. View

11.

Reichert T, Sugaya N, Fedson D, Glezen W, Simonsen L, Tashiro M . The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001; 344(12):889-96. DOI: 10.1056/NEJM200103223441204. View

12.

Van Tilbeurgh M, Lemdani K, Beignon A, Chapon C, Tchitchek N, Cheraitia L . Predictive Markers of Immunogenicity and Efficacy for Human Vaccines. Vaccines (Basel). 2021; 9(6). PMC: 8226531. DOI: 10.3390/vaccines9060579. View

13.

Paste M, Stoffel M, Bardone C, Baron-Papillon F, Czwarno A, Galbraith H . Addressing vaccine supply challenges in Europe: Expert industry perspective and recommendations. Health Policy. 2021; 126(1):35-42. DOI: 10.1016/j.healthpol.2021.11.006. View

14.

Somes M, Turner R, Dwyer L, Newall A . Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: A systematic review and meta-analysis. Vaccine. 2018; 36(23):3199-3207. DOI: 10.1016/j.vaccine.2018.04.063. View

15.

Olliaro P, Torreele E, Vaillant M . COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. Lancet Microbe. 2021; 2(7):e279-e280. PMC: 8057721. DOI: 10.1016/S2666-5247(21)00069-0. View